1 0

    Anti-Human CD20 Monoclonal Antibody(Ofatumumab)

    Anti-Human CD20 Monoclonal Antibody(Ofatumumab)

    Catalog Number: UA016238 Brand: UA BIOSCIENCE
    Share:
    Price:
    $685 USD
    $685 USD
    Size:

    For shipping services or bulk orders, you may request a quotation.
    Secure checkout with
    View full details

    Product Details

    Product Specification


    Host Human
    Synonyms Ofatumumab
    Concentration 2mg/mL
    Expression System HEK293
    Conjugation Unconjugated
    Physical Appearance Liquid
    Storage Buffer

    PBS pH7.4, containing no preservative
    Stability & Storage

    2 to 8 °C for 2 weeks under sterile conditions;

    -20 °C for 3 months under sterile conditions;

    -80 °C for 24 months under sterile conditions.

    Please avoid repeated freeze-thaw cycles.
    Reference

    1. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.
    2. Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022 Sep;28(10):1562-1575.

    Background

    Ofatumumab is a fully humanized monoclonal antibody that targets the CD20 molecule on the surface of B cells. Its core mechanism of action involves binding to the CD20 protein, thereby triggering multiple effector functions—including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis—to efficiently deplete CD20-positive B lymphocytes. Clinically, ofatumumab has a dual application: the intravenous formulation (Arzerra®) is indicated for the treatment of chronic lymphocytic leukemia, while the subcutaneous formulation (Kesimpta®) has been approved for the management of adult relapsing forms of multiple sclerosis, effectively reducing relapse rates and delaying disability progression. Notably, its convenient once‑monthly, at‑home self‑administration regimen offers significant advantages in facilitating long‑term disease management for patients with multiple sclerosis.

    Picture

    ELISA

    Immobilized Anti-Human CD20 Monoclonal Antibody (Ofatumumab) (Cat. No. UA016238) at 2μg/mL (100 μL/well) can bind Biotinylated CD20 Flag&Avi Tag Full Length Protein, Human (Detergent) (Cat. No. UA060040) with a linear range of 33.92-41.79 ng/mL.